Xilio Therapeutics Inc

-0.08 (-3.20%)
Earnings Announcements

Xilio Therapeutics Announces Third Quarter Results

Published: 11/09/2022 15:30 GMT
Xilio Therapeutics Inc (XLO) - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results.
Xilio Therapeutics Inc - Anticipates Existing Cash and Equivalents Will Be Sufficient to Fund Operating Expenses and Capex Requirements Into Q2 2024.
Xilio Therapeutics Inc Qtrly Net Loss per Share $0.72.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.80

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.03

More details on our Analysts Page.